Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Colorcon
McKinsey
Baxter

Last Updated: August 19, 2022

Investigational Drug Information for GS-9857


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for GS-9857?

GS-9857 is an investigational drug.

There have been 15 clinical trials for GS-9857. The most recent clinical trial was a Phase 3 trial, which was initiated on December 23rd 2015.

The most common disease conditions in clinical trials are Hepatitis C, Infections, and Infection. The leading clinical trial sponsors are Gilead Sciences, Unity Health Care, Inc., and University of Maryland.

There are thirty-two US patents protecting this investigational drug and eight hundred and twenty-eight international patents.

Recent Clinical Trials for GS-9857
TitleSponsorPhase
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionGilead SciencesPhase 3
Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment StudyGilead SciencesPhase 3
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA ExperienceGilead SciencesPhase 2

See all GS-9857 clinical trials

Clinical Trial Summary for GS-9857

Top disease conditions for GS-9857
Top clinical trial sponsors for GS-9857

See all GS-9857 clinical trials

US Patents for GS-9857

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-9857 See Plans and Pricing Synthesis of an antiviral compound GILEAD SCIENCES, INC. (Foster City, CA) See Plans and Pricing
GS-9857 See Plans and Pricing Combination formulation of two antiviral compounds Gilead Pharmasset LLC (Foster City, CA) See Plans and Pricing
GS-9857 See Plans and Pricing Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA) See Plans and Pricing
GS-9857 See Plans and Pricing Inhibitors of hepatitis C virus Gilead Pharmasset LLC (Foster City, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-9857

Drugname Country Document Number Estimated Expiration Related US Patent
GS-9857 Argentina AR098959 2033-12-23 See Plans and Pricing
GS-9857 Australia AU2014370125 2033-12-23 See Plans and Pricing
GS-9857 Canada CA2934537 2033-12-23 See Plans and Pricing
GS-9857 China CN105849118 2033-12-23 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Colorcon
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.